Novartis | NOVN - Net Income

Stock Price
119.50
Daily Change
-2.28 -1.87%
Monthly
-5.52%
Yearly
21.64%
Q1 Forecast
118.31

Novartis reported $3.93B in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alcon AG USD 217M 20M Dec/2025
Almirall EUR 19.58M 7M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Autolus Therapeutics Ltd USD -79.12M 31.2M Sep/2025
Bayer EUR -3.76B 2.79B Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Eli Lilly USD 6.64B 1.05B Dec/2025
Fresenius EUR 361M 17M Dec/2025
Fresenius Medical Care EUR 327M 52.2M Dec/2025
Galapagos EUR 782.15M 984.26M Dec/2025
Genmab DKK 336M 141M Jun/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
GRIFOLS EUR 98.25M 28.72M Dec/2025
Hikma Pharmaceutical USD 164M 45M Dec/2025
J&J USD 5.12B 36M Dec/2025
Lonza CHF 307M 22M Dec/2024
Merck EUR 319M 583M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 3.93B 96M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Novo Nordisk DKK 26.89B 388M Dec/2025
Orion EUR 260.5M 164.5M Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Philips EUR 395M 211M Dec/2025
Recordati EUR 117.31M 7.15M Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
UCB EUR 857M 649M Dec/2024